Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 330

The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.

Everolimus With Reduced Tacrolimus Improves Renal Function in De Novo Liver Transplant Recipients: A Randomized Controlled Trial

Open access
De Simone, P., Nevens, F., De Carlis, L., Metselaar, H.J., Beckebaum, S., Saliba, F., Jonas, S., Sudan, D., Fung, J., Fischer, L., Duvoux, C., Chavin, K.D., Koneru, B., Huang, M.A., Chapman, W.C., Foltys, D., Witte, S., Jiang, H., Hexham, J.M., Junge, G.·2012·American Journal of Transplantation

Abstract

In a prospective, multicenter, open-label study, de novo liver transplant patients were randomized at day 30±5 to (i) everolimus initiation with tacrolimus elimination (TAC Elimination) (ii) everolimus initiation with reduced-exposure tacrolimus (EVR+Reduced TAC) or (iii) standard-exposure tacrolimus (TAC Control). Randomization to TAC Elimination was terminated prematurely due to a higher rate of treated biopsy-proven acute rejection (tBPAR). EVR+Reduced TAC was noninferior to TAC Control for the primary efficacy endpoint (tBPAR, graft loss or death at 12 months posttransplantation): 6.7% versus 9.7% (-3.0%; 95% CI -8.7, 2.6%; p<0.001 for noninferiority [12% margin]). tBPAR occurred in 2.9% of EVR+Reduced TAC patients versus 7.0% of TAC Controls (p = 0.035). The change in adjusted estimated GFR from randomization to month 12 was superior with EVR+Reduced TAC versus TAC Control (difference 8.50 mL/min/1.73 m(2) , 97.5% CI 3.74, 13.27 mL/min/1.73 m(2) , p<0.001 for superiority). Drug discontinuation for adverse events occurred in 25.7% of EVR+Reduced TAC and 14.1% of TAC Controls (relative risk 1.82, 95% CI 1.25, 2.66). Relative risk of serious infections between the EVR+Reduced TAC group versus TAC Controls was 1.76 (95% CI 1.03, 3.00). Everolimus facilitates early tacrolimus minimization with comparable efficacy and superior renal function, compared to a standard tacrolimus exposure regimen 12 months after liver transplantation.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1600-6143.2012.04212.x

Cites

28 of 28 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 28 references

Cited by

See all 330

Metadata

Authors
De Simone, P., Nevens, F., De Carlis, L., Metselaar, H. J., Beckebaum, S., Saliba, F., Jonas, S., Sudan, D., Fung, J., Fischer, L., Duvoux, C., Chavin, K. D., Koneru, B., Huang, M. A., Chapman, W. C., Foltys, D., Witte, S., Jiang, H., Hexham, J. M., & Junge, G.
Venue
American Journal of Transplantation
Publisher
Elsevier BV
Published
2012-11
Volume
12
Issue
11
Pages
3008-3020
ISSN
1600-6135 (ISSN-L)
OpenAlex
W1604773174
Cited by
330
References
28
FWCI
25.86
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Everolimus With Reduced Tacrolimus Improves Renal Function in De Novo Liver Transplant Recipients: A Randomized Controlled Trial. https://app.cochat.ai/papers/10.1111/j.1600-6143.2012.04212.x
The paper
De Simone, P., Nevens, F., De Carlis, L., Metselaar, H. J., Beckebaum, S., Saliba, F., Jonas, S., Sudan, D., Fung, J., Fischer, L., Duvoux, C., Chavin, K. D., Koneru, B., Huang, M. A., Chapman, W. C., Foltys, D., Witte, S., Jiang, H., Hexham, J. M., & Junge, G. (2012). Everolimus With Reduced Tacrolimus Improves Renal Function in De Novo Liver Transplant Recipients: A Randomized Controlled Trial. American Journal of Transplantation. https://doi.org/10.1111/j.1600-6143.2012.04212.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.